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Despite recent advances in conventional therapeutic approaches for cancer, the frequently observed acquired drug resistance and toxic side
effects have limited their clinical application. The main goal of this work was to investigate the combined antitumoral effect of vinblastine with
HSV-Tk/GCV “suicide” gene therapy mediated by human serum albumin (HSA)-associated lipoplexes, in mammary adenocarcinoma cells (TSA
cells). Our results show that, among the different lipoplex formulations tested, HSA-associated complexes prepared from EPOPC:Chol liposomes,
at the (4/1) (+/−) charge ratio, was the most efficient to mediate gene delivery, even in the presence of serum. The simultaneous addition of
vinblastine and HSA-EPOPC:Chol/DNA (+/−) (4/1) lipoplexes to TSA cells improved transgene expression more than 10 times. When combined
with the HSV-Tk/GCV “suicide” gene therapy mediated by HSA-EPOPC:Chol/DNA (+/−) (4/1) lipoplexes, vinblastine induced a great
enhancement in the antitumoral activity in TSA cells. Most importantly, this combined strategy resulted in a significant synergistic effect, thus
allowing the use of a much lower dose of the drug to achieve the same therapeutic effect. Overall, our results indicate that this approach has the
potential to overcome some major limitations of conventional chemotherapy, and may therefore constitute a promising strategy for future
applications in antitumoral therapy.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cancer gene therapy; “Suicide” gene therapy; Vinblastine; Gene delivery; Cationic liposomes; Transfection1. Introduction
One of the major challenges in the application of gene
therapy as a therapeutic tool is to overcome the inefficient
delivery of therapeutic genes into target cells. To this regard,
many efforts have been made to develop efficient, safe and
stable gene delivery systems [1–4]. In the process of gene
delivery, many cellular obstacles have to be overcome to
achieve satisfactory levels of transfection activity: binding of
lipoplexes to the cell surface; uptake of the lipoplexes, endo-
cytosis being the main pathway; escape of lipoplexes from the
endolysosomal compartment and translocation through the nu-
clear envelope [5–9]. In this context, different strategies have⁎ Corresponding author. Center for Neuroscience and Cell Biology, University
of Coimbra, 3000 Coimbra, Portugal. Tel.: +351 239 820 190; fax: +351 239
853 607.
E-mail address: mdelima@ci.uc.pt (M.C. Pedroso de Lima).
0168-3659/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.jconrel.2007.12.005been developed to surpass these barriers aiming at enhancing
transgene expression. For instance, in accordance with our
previous observations, the association of HSA to lipoplexes
seems to be a promising strategy resulting in an enhancement of
transgene expression in different types of cells, even in the
presence of serum [10,11]. This increase of tranfection ef-
ficiency most likely results from the promotion of lipoplex
internalization via endocytosis and escape from the endocytotic
pathway.
In the last years, gene therapy has emerged as a promising
strategy for cancer treatment [12–14]. The “suicide” gene
approach is a cancer gene therapy strategy that consists of the
transfer into cancer cells of a “suicide” gene, which encodes the
enzyme responsible for the conversion of an inactive drug into a
toxic metabolite that causes cell death [15,16]. Herpes Simplex
Virus thymidine kinase gene (HSV-tk) is one of the most
promising “suicide” genes, ganciclovir (GCV) being its re-
spective prodrug [17–19]. Cells expressing the HSV-tk gene
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ther converted into ganciclovir triphosphate by cellular kinases.
As the resulting compound is an analogue of deoxyguanosine
triphosphate, inhibiton of DNA polymerase and/or incorpora-
tion into DNA will occur, leading to chain termination and
tumoral cell death [17–19]. A crucial element of HSV-Tk/GCV
gene therapy is the “bystander effect”, by which a high per-
centage of tumoral cell death can occur even when only a low
percentage of cells have been transfected [10,20–22].
Vinblastine is a chemotherapeutic drug that belongs to the
class of microtubule-depolymerizing agents and binds specifi-
cally to tubulin, inhibiting its polymerization and the subse-
quent association of microtubules. As the microtubules are
crucial for the occurrence of chromosomal segregation during
anaphase in mitosis, the resulting depolymerization of this cy-
toskeleton element results in a G2-M cell cycle arrest and
consequently in cell death [23]. However, microtubules are not
only involved in the chromosomal segregation, but also play
important roles in intracellular dynamics, including the
transport of lipoplexes to lysosomes after their uptake through
endocytosis [24–26]. The compounds that affect the depoly-
merization state of microtubules may be used to enhance the
transfection capacity of lipoplexes, by helping to overcome the
endolysosomal entrapment, and consequently DNA degrada-
tion at the lysosomal level [24–26]. Moreover, it has been
reported that these agents can increase transfection efficiency of
cationic liposome/DNA complexes by activating the sequence-
specific transcription factor NF-κB [23,24,27].
Therefore, our hypothesis is that vinblastine could act in
concert with HSV-Tk/GCV “suicide” gene therapy, by increas-
ing lipoplex biological activity and inhibiting mitosis, thus
leading to a synergistic antitumoral effect. In this context, the
main goal of this work was to evaluate the effect of this drug on
transgene expression mediated by cationic liposomes and the
antitumoral activity of a combined strategy involving associa-
tion of vinblastine and HSV-Tk/GCV “suicide” gene therapy
mediated by HSA-associated lipoplexes, in mouse mammary
adenocarcinoma cells in culture.
2. Material and methods
2.1. Cells
TSA cells (BALB/c female mouse mammary adenocarcinoma
cell line) were maintained at 37 °C, under 5%CO2, in Dulbecco's
modified Eagle's medium-high glucose (DMEM-HG) (Irvine
Scientific, Santa Ana, CA) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS) (Sigma, St. Louis, MO),
penicillin (100 U/ml) and streptomycin (100 μg/ml). TSA cells
grow in monolayer and were detached by treatment with a trypsin
solution (0.25%) (Sigma, St. Louis, MO).
2.2. Preparation of cationic liposomes and their complexes
with DNA
Small unilamellar cationic liposomes (SUV) were prepared
by extrusion of multilamellar liposomes (MLV) composed of1:1 (mol ratio) mixtures of (1) 1,2-dioleoyl-3-(trimethylammo-
nium) propane (DOTAP) and cholesterol (Chol), (2) 1-
palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine
(EPOPC) and dioleoylphosphatidylethanolamine (DOPE), or
(3) EPOPC and Chol; and composed of a 2:1:1 (mol ratio)
mixture of (4) EPOPC, DOPE and Chol. EPOPC:Chol (1:1)
liposomes were labeled with 1% rhodamine-dioleoylphospha-
tidylethanolamine (rhodamine-PE), for binding and uptake
studies, and with 0.1% carboxyfluorescein-dioleoylphosphati-
dylethanolamine (carboxyfluorescein-PE), for intracellular dis-
tribution studies. Briefly, lipids (Avanti Polar Lipids, Alabaster,
AL) dissolved in CHCl3 were mixed at the desired molar ratio
and dried under vacuum in a rotatory evaporator. The dried lipid
films were hydrated with deionized water to a final lipid con-
centration of 6 mM and the resulting MLV were then sonicated
for 3 min and extruded 21 times through two stacked poly-
carbonate filters of 50 nm pore diameter using a Liposofast
device (Avestin, Toronto, Canada). The resulting liposomes
(SUV) were then diluted five times with deionized water and
filter-sterilized utilizing 0.22 μm pore-diameter filters (Schlei-
cher & Schuell, Dassel, Germany). The suspension was stored
at 4 °C until use. Lipoplexes were prepared by sequentially
mixing 100 μl of a HEPES-buffered saline solution (HBS)
(100 mM NaCl, 20 mM HEPES, pH 7.4), with liposomes (the
volume necessary to obtain the desired (+/−) lipid/DNA charge
ratio) and with 100 μl of HBS solution containing 1 μg of
pCMVluc encoding luciferase (a gift of Dr. P. Felgner, Vical,
San Diego, CA), 1 μg of pCMVtk encoding HSV-tk (a gift of
Prof. N. Düzgünes, University of Pacific, San Francisco, USA),
or 1 μg of pCMVgfp, encoding green fluorescent protein (GFP)
(Clontech, Mountain View, CA). The mixtures were further
incubated for 15 min at room temperature. For lipoplexes con-
taining HSA (Sigma, St. Louis, MO), liposomes were pre-
incubated with this protein (32 μg HSA/μg of DNA) for 15 min,
followed by a further 15 min incubation with plasmid DNA
solution at room temperature. Lipoplexes were used immedi-
ately after being prepared.
2.3. Transfection activity
For transfection studies with complexes containing the plas-
mids pCMVluc or pCMVtk, 0.4×105 TSA cells were seeded in
1 ml of medium in 48-well culture plates 24 h before trans-
fection, in order to obtain 50–70% confluence. Cells were
covered with 0.3 ml of DMEM-HG (without serum, unless
indicated otherwise) before lipoplexes (containing 1 µg of
DNA) were gently added in a volume of 0.2 ml per well,
without or with different amounts of Vinblastine (depending
on the desired concentration). After 4 h incubation (5% CO2 at
37 °C) the medium was replaced with DMEM-HG and the cells
were further incubated for 48 h. Cells were then washed twice
with phosphate-buffered saline solution (PBS) and 150 μl of
lysis buffer (1 mM DTT; 1 mM EDTA; 25 mM Tris-phosphate
(pH=7.8); 8 mM MgCl2; 15% glycerol; 1% (v/v) Triton X-
100) were added to each well. The level of gene expression in
the lysates was evaluated by measuring light production by
luciferase in a LMax II 384 luminometer (Molecular Devices,
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measured by the Dc Protein Assay reagent (Bio-Rad, Hercules,
CA) using bovine serum albumin as the standard. The data
were expressed as RLU of luciferase per mg of total cell
protein.
For transfection studies with complexes containing the
plasmid pCMVgfp, 1.2×105 TSA cells were seeded in 2 ml of
medium in 12-well culture plates (previously covered with a
coverslip), 24 h before transfection. Cells were covered with
0.5 ml of DMEM-HG before lipoplexes (containing 2 µg of
DNA) were added in the presence or absence of 0.5 µM
vinblastine. Following 48 h after the initial transfection period
(4 h), cells were fixed with 4% paraformaldehyde, for 15 min
at room temperature, the nuclei were labeled with the fluo-
rescent DNA-binding dye Hoechst 33342 (1 µg/ml), for 5 min
at room temperature, and then cells were mounted in Vecta
Shield mounting medium (Vecta Laboratories Inc., Burlin-
game, CA, USA). Images were taken using a confocal micro-
scope (LSM-510 META, Zeiss), under the 63x oil immersion
objective.
2.4. Cell viability assay
Following transfection under the different experimental
conditions, cell viability was assessed by a modified Alamar
Blue assay [28]. The assay measures the redox capacity of
the cells due to the production of metabolites as a result of
cell growth and allows determination of viability over the
period culture without the detachment of adherent cells. Brief-
ly, 0.4 ml of 10% (V/V) Alamar Blue dye in complete DMEM-
HG medium was added to each well 45 h following the initial
transfection period (4 h). After 1 h of incubation at 37 °C, 200 µl
of the supernatant were collected from each well and trans-
ferred to 96-well plates. The absorbance at 570 and 600 nm
was measured in a SPECTRAmax PLUS 384 spectrophot-
ometer (Molecular Devices, Union City, CA). Cell viability
(as a percentage of control cells) was calculated according to
the formula (A570−A600) of treated cells×100 / (A570−A600) of
control cells.
2.5. Antitumoral activity
The in vitro antitumoral activity mediated by non-viral
HSV-Tk/GCV gene therapy, vinblastine or their combination
was evaluated in TSA cells. Since the production of ganci-
clovir was discontinued, its prodrug valganciclovir (VGCV),
an L-valyl ester of GCV, was used. Following 4 h incubation
of TSA cells with HSA-associated lipoplexes or HBS, in the
presence or absence of 0.5 µM vinblastine, the medium was
replaced with normal DMEM-HG. Twenty-four hours after,
the medium was replaced with DMEM-HG with or with-
out different concentrations of VGCV (100, 200 or 400 µM)
and cells were further incubated for 5 days under cultured
conditions (5% CO2 at 37 °C). The medium, with or without
VGCV, was replaced daily and the cell viability was assessed
every other day by the modified Alamar Blue assay as referred
above.2.6. Binding and uptake of lipoplexes
EPOPC:Chol (1:1) liposomes, labeled with 1% rhodamine-
PE, were complexed in the presence or absence of HSA, with
1 µg of pCMVluc at a 4/1 (+/−) cationic lipid/DNA charge ratio.
Twenty-four hours before transfection, 0.5×105 TSA cells were
seeded in 1 ml of medium in 48-well culture plates. After
covering the cells with 0.3 ml of DMEM-HG medium,
lipoplexes were added in the presence or absence of 0.5 µM
vinblastine. Following a 2 h incubation at 4 °C or 37 °C, cells
were washed twice with PBS and lysed with 100 μl/well of 1%
Triton X-100. Binding (4 °C) and uptake (37 °C) of lipoplexes
were monitored in a SPECTRAmax GEMINI EM fluorometer
(Molecular Devices, Union City, CA) by measuring the
fluorescence at excitation and emission wavelengths of 545
and 587 nm, respectively.
2.7. Intracellular distribution of lipoplexes
Twenty-four hours before transfection, 1.2×105 TSA cells
were added to each well of a 12-well culture plate, previously
covered with a coverslip.
To observe the intracellular distribution of the complexes,
EPOPC:Chol liposomes labelled with 0.1% carboxyfluores-
cein-PE and associated to HSA, were complexed with 2 µg of
pCMVluc at the (4/1) (+/−) charge ratio. Cells were incubated,
during 30 min, with 200 nM LysoTracker Red DND-99
(Molecular Probes), which labels acidic compartments of live
cells, and then covered with 0.5 ml of DMEM-HG medium
before lipoplexes were added in the presence or absence of
0.5 µM vinblastine. After 2 h of incubation, the nuclei were
labeled with the fluorescent DNA-binding dye Hoechst 33342
(1 µg/ml), for 5 min at room temperature, and cells were
mounted in Vecta Shield mounting medium (Vecta Laboratories
Inc., Burlingame, CA, USA). Images were taken with a con-
focal microscope (LSM-510 META, Zeiss), under the 63x oil
immersion objective.
2.8. Statistical analysis
Data were analysed using the Prism software (version 4.0).
Statistical significance of differences between data was eval-
uated by One-way ANOVA using the Tukey test. A value of
pb0.05 was considered significant.
3. Results
3.1. Biological activity and cytotoxicity of the complexes
There are several parameters that affect the final physico-
chemical properties of lipoplexes and consequently the levels of
transfection mediated by these non-viral gene carriers [1–4].
The nature of the cationic and helper lipids and the relative
proportion of cationic lipid and DNA are examples of two
crucial parameters that should be considered in the preparation
of lipoplexes. In the present work, cationic lipid/DNA com-
plexes with various lipid compositions and prepared at different
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activity in TSA cells.
Fig. 1A shows that the biological activity mediated by lipo-
plexes in TSA cells was dependent on their charge ratio (+/−)
and lipid composition. Among the different formulations tested,
EPOPC:Chol/DNA and DOTAP:Chol/DNA complexes were
those exhibiting the highest levels of transfection (pb0.001 and
pb0.01, respectively). Since the biological activity of the com-
plexes could be affected by their cytotoxicity, cell viability
studies were performed for the tested formulations. The results
presented in Fig. 1B reveal that the viability of TSA cells was
not significantly affected (pN0.05) upon incubation with the
complexes, similar results being observed for the different
formulations.
Our previous results demonstrated that association of albu-
min to lipoplexes is highly effective in enhancing transfectionFig. 1. Effect of lipoplex composition and charge ratio (+/−) on luciferase gene
expression (A) and viability (B) in TSA cells. Liposomes with different lipid
composition were complexed with pCMVluc at the indicated (+/−) charge
ratios. (A) Levels of luciferase gene expression are presented as RLU of
luciferase per mg of total cell protein (mean±S.D. obtained from triplicates),
and are representative of at least three independent experiments. Asterisks
(⁎⁎pb0.01, ⁎⁎⁎pb0.001), for the two best conditions, indicate values that
significantly differ from those measured for the other conditions. (B) Values of
cell viability measured by the Alamar Blue assay are expressed as the percentage
of the untreated control cells (mean±standard deviation obtained from
triplicates) and are representative of at least three independent experiments.
Fig. 2. Effect of albumin association to EPOPC:Chol/DNA lipoplexes on
luciferase gene expression in TSA cells. Lipoplexes, prepared with or without
HSA, were incubated with cells in the presence or absence of 10% serum. Levels
of luciferase gene expression are presented as RLU of luciferase per mg of total
cell protein (mean±S.D. obtained from triplicates), and are representative of at
least three independent experiments. Asterisks (⁎⁎pb0.01, ⁎⁎⁎pb0.001)
correspond to data from cells treated with HSA-associated lipoplexes which
significantly differ from those obtained with cells treated with complexes
prepared at the same charge ratio but without HSA.
Fig. 3. Effect of vinblastine concentration on the transfection activity mediated
by HSA-EPOPC:Chol/DNA lipoplexes in TSA cells. Cells were simultaneous
incubated with lipoplexes and vinblastine (0.05; 0.1; 0.25; 0.5; 2 or 5 µM).
Levels of luciferase gene expression are presented as RLU of luciferase per mg
of total cell protein (mean±S.D. obtained from triplicates), and are
representative of at least three independent experiments. Asterisks
(⁎⁎⁎pb0.001), for the two best conditions, indicate values that significantly
differ from those measured for all the other vinblastine concentrations at the
same charge ratios.
Fig. 4. Effect of vinblastine on gene delivery mediated by HSA-EPOPC:Chol/
DNA lipoplexes in TSA cells. Representative confocal microscopy images
(original magnification: ×630) of gene delivery mediated by (A) HSA-EPOPC:
Chol/DNA (+/−) (4/1) lipoplexes and (B) HSA-EPOPC:Chol/DNA (+/−) (4/1)
lipoplexes+0.50 µM vinblastine. TSA cells with Hoechst-labelled nuclei (blue)
were transfected with lipoplexes containing the GFP plasmid.
Fig. 5. Effect of vinblastine on the extent of binding and uptake of EPOPC:Chol/
DNA and HSA-EPOPC:Chol/DNA lipoplexes in TSA cells. Liposomes,
labelled with rhodamine-PE, were associated or not to HSA before complexa-
tion with DNA. Cells were incubated for 2 h with the lipoplexes at 4 °C
(binding) or 37 °C (uptake), in the presence or absence of 0.5 µM vinblastine
(Vinb). The data are expressed as RFU per 106 cells (mean±S.D. obtained from
triplicates), and are representative of three independent experiments. Asterisks
(⁎⁎⁎pb0.001) correspond to data from cells treated with HSA-associated
lipoplexes which significantly differ from those obtained with cells treated with
complexes prepared without HSA.
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present work, we tested this strategy in TSA cells for the two
best liposome formulations, EPOPC:Chol and DOTAP:Chol,
complexed with pCMVluc at the (1/1), (2/1) and (4/1) (+/−)
charge ratios, in the presence or absence of serum. Fig. 2
illustrates the effect of albumin association to EPOPC:Chol/
DNA complexes on their biological activity. As can be ob-
served, a great enhancement of transgene expression occurred
particularly at the 2/1 and 4/1 (+/−) charge ratios (pb0.01
and pb0.001, respectively). As also shown in Fig. 2, when
transfection experiments were performed in the presence of
serum, a significant reduction in transgene expression was
observed for plain lipoplexes, at all the charge ratios tested.
However, resistance to the inhibitory effect of serum on
biological activity was achieved for HSA-EPOPC:Chol/DNA
lipoplexes prepared at the (4/1) (+/−) charge ratio (pb0.001).
The association of HSA to DOTAP:Chol/DNA lipoplexes
also resulted in an enhancement of the transfection activity (data
not shown), although to a lesser extent than that obtained for
EPOPC:Chol/DNA lipoplexes. For this reason, the HSA-
EPOPC:Chol/DNA lipoplexes were selected for further studies.3.2. Effect of vinblastine on transfection activity of HSA-
EPOPC:Chol/DNA lipoplexes
Since the main goal of this work was to evaluate tumoral cell
death resulting from the combination of vinblastine and non-
viral HSV-tk/GCV gene therapy, we investigated whether this
anti-cancer drug would have any effect as an enhancer of
transfection activity mediated by lipoplexes. For this purpose,
we addressed the effect of different concentrations of vinblas-
tine on luciferase gene expression in TSA cells, mediated by
HSA-EPOPC:Chol/DNA complexes prepared at (2/1) and (4/1)
(+/−) charge ratios. As can be observed in Fig. 3, the presence of
the chemotherapeutic agent resulted in an increase of the
biological activity of the complexes. This enhancing effect was
concentration-dependent, being maximal at 0.5 µM vinblastine
(pb0.001), for both charge ratios (Fig. 3). Remarkably, at this
concentration, vinblastine induced a 10-fold increase in the
transfection activity, even in the presence of serum (data not
shown).
For all the vinblastine concentrations tested, the 4/1 lipid/
DNA (+/−) charge ratio allowed greater levels of transgene
expression than the 2/1 (+/−) charge ratio, and therefore, HSA-
EPOPC:Chol/DNA (+/−) (4/1) lipoplexes were selected for
further studies, namely those involving the delivery of the
therapeutic gene.
The effect of vinblastine on transfection mediated by HSA-
EPOPC:Chol/DNA (+/−) (4/1) lipoplexes was also examined in
TSA cells by confocal microscopy, in terms of the levels and
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percentage of GFP-expressing cells and the intensity of GFP
fluorescence were higher in the presence of 0.5 µM of vin-
blatine. This observation is in agreement with the high levels of
luciferase gene expression obtained in the presence of the same
vinblastine concentration (Fig. 3).Fig. 6. Effect of vinblastine on the intracellular distribution of HSA-EPOPC:C
magnification: ×630) of intracellular distribution, in TSA cells, of (A) HSA-EPOPC
lipoplexes+0.5 µM vinblastine. (i) Endolysosomal pathway labelled with 200 M of L
Co-localization of the lipoplexes and endolysosomal pathway in TSA cells with Ho3.3. Binding and uptake of lipoplexes
To investigate whether the enhancing effect of vinblastine on
the biological activity of the complexes was due to an increase
of binding and/or internalization of lipoplexes, TSA cells were
incubated with rhodamine-PE-labeled EPOPC:Chol/DNA (+/−)hol/DNA lipoplexes. Representative confocal microscopy images (original
:Chol/DNA (+/−) (4/1) lipoplexes and (B) HSA-EPOPC:Chol/DNA (+/−) (4/1)
ysoTracker Red DND-99; (ii) Lipoplexes labelled with carboxyfluorescein; (iii)
echst-labelled nuclei.
Fig. 7. Effect of valganciclovir concentration and incubation time on cell
viability. TSA cells were incubated with HSA-EPOPC:Chol/DNA (+/−) (4/1)
lipoplexes, containing 1 µg of pCMVtk plamid, or HBS (non-transfected cells),
in the presence or absence of 0.5 µM vinblastine. Following 24 h, the medium
was replaced with DMEM-HG (control cells and untreated cells with VGCV) or
with DMEM-HG containing different concentrations of VGCV (100, 200 or
400 µM). Medium was replaced daily and cell viability measured by Alamar
Blue assay. The data are expressed as the percentage of the untreated control
cells (mean±standard deviation obtained from triplicates) and are representative
of at least four independent experiments. The results illustrated in (B)
correspond to the cell viability measured at the fifth day of treatment. Asterisks
(⁎⁎pb0.01, ⁎⁎⁎pb0.001) indicate values that significantly differ from those
measured for non-treated cells (control). Cardinals (###pb0.001) correspond to
data from cells treated with the combined therapy which significantly differ from
those obtained with cells treated with each strategy alone.
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(4/1) lipoplexes at 4 °C (binding) and 37 °C (uptake), in the
presence or absence of 0.5 µM of vinblatine.
As can be observed in Fig. 5, association of albumin to
lipoplexes resulted in a significant enhancement in the extent of
binding (pb0.001) and uptake (pb0.001). On the other hand,
the presence of vinblastine did not induce any significant
change in the binding and uptake levels of HSA-EPOPC:Chol/
DNA (+/−) (4/1) lipoplexes (Fig. 5).
3.4. Intracellular distribution of HSA-EPOPC:Chol/DNA
lipoplexes
We also examined the influence of vinblastine on the intra-
cellular distribution of HSA-EPOPC:Chol/DNA (+/−) (4/1)
lipoplexes by confocal microscopy. The endolysosomal path-
way of TSA cells was labelled with LysoTracker Red, which
labels acidic compartments in live cells, while the intracellular
localization of the lipoplexes was visualized by incorporating
carboxyfluorescein-PE into the liposomal membrane.
As shown in Fig. 6, in the presence of vinblastine HSA-
lipoplexes accumulated in a lower extent in the endolysosomal
pathway, being more concentrated near the nuclei. These ob-
servations suggest that vinblastine most likely facilitates de-
livery of the complexes from the endocytotic pathway. On the
other hand, this drug did not interfere with the cellular uptake of
HSA-associated lipoplexes (identical intensity levels of GFP
fluorescence in Fig. 6 A and B), which is in agreement with the
results shown in Fig. 5.
3.5. Antitumoral activity
The main goal of this study was to evaluate the therapeutic
potential resulting from the combination of two antitumoral
strategies: HSV-Tk/GCV suicide gene therapy and conventional
chemotherapy. For this purpose, TSA cells were treated with
vinblastine (chemotherapeutic agent) or transfected with HSA-
EPOPC:Chol/DNA (+/−) (4/1) lipoplexes carrying the pCMVtk
plasmid, in the presence (combined therapy) or absence of
0.5 µM vinblastine, and then incubated for five days with
different concentrations of valganciclovir (VGCV).
As shown in Fig. 7, the cytotoxic effect induced by the
combined or HSV-tk/GCV gene therapy approaches is depen-
dent both on VGCV concentration and incubation time. The
most effective concentration was 400 µM VGCV, no significant
differences being observed for the extent of cytotoxicity in-
duced by 100 or 200 µM VGCV. For all tested strategies, the
highest reduction in cell viability was obtained at the fifth day of
treatment.
In the absence of vinblastine 54% of cell death (pb0.001)
was achieved after transfection followed by five days of treat-
ment with 400 µM VGGV. On the other hand, for non-trans-
fected cells that were treated with 0.5 µM vinblastine, only 10%
reduction of cell viability was obtained. However, for cells
that were transfected in the presence of 0.5 µM vinblastine
(combined therapy), five days of treatment with 400 µMVGGV
resulted in an almost total cell death (98% of cytotoxicity),
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combination of these two therapeutic strategies. This synergistic
enhancement of cytotoxicity was observed for the three VGCV
tested concentrations (Fig. 7A). As illustrated in Fig. 7B (cell
viability for the fifth day of treatment), VGCV was non-toxic to
non-transfected cells, either per se or in the presence of 0.5 µM
vinblastine, and no significant toxicity was induced upon trans-
fection of cells in the absence of VGCV treatment. Under these
control conditions no significant toxicity was observed for days
1 and 3 of treatment (data not shown). Therefore, the reduction
in cell viability observed in transfected cells after treatment with
VGCV is not due to VGCV itself or to the transfection protocol.
4. Discussion
Due to their simplicity, ease of large-scale production and
lack of specific immune response, cationic liposome/DNA
complexes constitute a promising tool for delivery of thera-
peutic genes in genetic and acquired human diseases. However,
the transgene expression mediated by these non-viral carriers is
inefficient, specially in vivo, being highly influenced by their
physico-chemical properties [1–4,29]. In this context, the iden-
tification, understanding and the modulation of these para-
meters are crucial to develop new efficient non-viral gene
delivery strategies.
As shown in Fig. 1, among the different liposome formu-
lations tested, EPOPC:Chol and DOTAP:Chol were those re-
sulting in complexes with the highest levels of transfection
(pb0.001 and pb0.01, respectively). In agreement with other
reports, these results show that the composition of the cationic
liposomes has a great importance for the biological activity of
the complexes [5,29]. On the other hand, the charge ratio of
lipid/DNA complexes is also a crucial factor in the lipofection
process, since it determines the surface charge and the mean
diameter of the complexes [5,6]. In this regard, for the most
efficient lipoplexes (EPOPC:Chol/DNA and DOTAP:Chol/
DNA), the highest transgene expression obtained for the com-
plexes with positive zeta potential, (2/1) and (4/1) (+/−) lipo-
plexes, can be explained by a greater extent of interaction with
the negatively charged cell membrane [29]. Although, the (4/1)
(+/−) lipoplexes exhibit a more positive surface charge than
those prepared at a (2/1) (+/−) charge ratio, they revealed a
lower biological activity than (2/1) (+/−) lipoplexes. This ob-
servation may be explained by the smaller sizes of the positively
charged (4/1) (+/−) complexes as compared to the (2/1) (+/−)
complexes and by the extensive condensation of genetic ma-
terial, which can limit the intracellular delivery of DNA, as
shown in our previous study [29].
Several approaches have been tested aiming at improving the
capacity of lipoplexes to mediate intracellular delivery of ge-
netic material. In agreement with our previous findings [10,11],
the results obtained in this work (Fig. 2) revealed that associ-
ation of albumin to lipoplexes is an efficient approach, resulting
in a great enhancement of transgene expression, although de-
pending on the lipid composition and cationic lipid/DNA (+/−)
charge ratio of lipoplexes. For the two tested liposome formu-
lations, EPOPC:Chol and DOTAP:Chol, the most pronouncedenhancing effect mediated by HSA was observed for EPOPC:
Chol/DNA complexes, particularly at the (4/1) (+/−) charge
ratio (pb0.001), even in the presence of serum (pb0.001). This
enhancing effect of albumin is most probably dependent on
the lipid nature of the liposomes, which may explain the
high transfection activity of HSA-EPOPC:Chol/DNA lipo-
plexes. The lipid nature could not only influence the capacity of
HSA to mediate the increase of biological activity, but could
also determine the final structure/properties of the complexes
containing HSA and consequently their transfection capacity
[11,30].
As indicated by the results from binding and uptake studies
(Fig. 5), association of HSA to EPOPC:Chol/DNA (4/1) (+/−)
lipoplexes resulted in a 3-fold enhancement (pb0.001) of
binding and cellular uptake. However, the biological activity
studies (Fig. 2) show that association of HSA to EPOPC:Chol/
DNA (4/1) (+/−) lipoplexes resulted in an increase of 15-fold
(pb0.001) in the levels of transgene expression. Since the
increase of transgene expression achieved upon HSA associa-
tion was nearly 5-fold higher than that for the increase in the
uptake of HSA-associated lipoplexes, it seems reasonable to
assume that HSA may act at two different stages of the endo-
cytotic pathway: by promoting binding/endocytosis of the lipo-
plexes and by facilitating escape of DNA from the endosome
[31–33].
The intracellular traffic of cationic liposome/DNA com-
plexes has been the subject of several studies aiming at iden-
tifying the cellular barriers that limit efficient gene delivery to
target cells. To this regard, the endolysosomal entrapment of
lipoplexes has been identified as one of the major limiting
factors of the transfection efficiency [5–9].
In this work, we tested the potential of the microtubule-
depolymerizing agent vinblastine to enhance transgene expres-
sion mediated by HSA-EPOPC:Chol/DNA lipoplexes in TSA
cells, probably by decreasing the intracellular traffic of lipo-
plexes to lysosomes and/or activating the transcription factor
NF-kb. In face of the wide clinical application of vinblastine as
an anticancer agent, gene delivery mediated by lipoplexes in the
presence of this drug may be an efficient antitumoral approach
due to its dual effect: enhancement of transgene expression
and chemotherapeutic activity. The results illustrated in Figs. 3
and 4 reveal that vinblastine significantly (pb0.001) improved
transgene (luciferase and GFP) expression in TSA cells, when
used at a concentration of 0.5 µM. The confocal microscopy
images of GFP gene expression (Fig. 4) show that such en-
hancement translated both into higher levels of gene expression
and larger percentage of transfected cells.
Aiming at gaining insights into the mechanisms involved
in the vinblastine effect, binding, uptake and intracellular
distribution studies were performed with HSA-EPOPC:Chol/
DNA (+/−) (4/1) lipoplexes in the presence of 0.5 µM
vinblastine. As shown in Figs. 5 and 6, the extent of in-
ternalized lipoplexes is similar in the presence and absence of
vinblastine, thus the potentiation of the transfection activity
mediated by this drug was not the result of the enhancement
of lipoplex uptake. This observation is consistent with the
reported role of actin rather than that of microtubules as the
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endocytosis [34,35]. Vinblastine probably enhances transgene
expression by decreasing the intracellular traffic of lipoplexes
to lysosomes and/or by activating the nuclear factor NF-κB
and consequently transgene transcription [23–27]. The low-
er accumulation of HSA-EPOPC:Chol/DNA lipoplexes ob-
served in the endolysosomal pathway in the presence of
vinblastine (Fig. 6) suggests that the depolymerization of the
microtubules results in fast delivery (escape) of the lipoplexes
from the endocytotic pathway. The small difference observed
for the intracellular distribution of lipoplexes in the presence
and absence of vinblastine can result from the association of
HSA to lipoplexes, since HSA can also promote their escape
from the endocytotic pathway, thus partially masking the
effect of vinblastine.
The effect of vinblastine on the antitumoral activity of the
HSV-tk/GCV “suicide” gene therapy mediated by HSA-asso-
ciated lipoplexes was evaluated in TSA cells and compared
with that observed upon application of the chemotherapeutic
agent and the gene therapy strategy (HSV-tk/GCV), sepa-
rately. The results illustrated in Fig. 7 reveal that the highest
antitumoral activity was observed for the combined therapy
(HSV-tk/VGCV gene therapy+vinblastine), at the fifth day of
treatment with 400 µM VGCV (~100% of cytotoxicity). The
huge difference (pb0.001) observed between the cytotoxicity
achieved by application of the combined therapy (~100%)
and that obtained for each strategy per se (54% for the gene
therapy strategy and 10% for the treatment with vinblastine)
clearly shows the occurrence of a synergistic effect. We have
also observed (data not shown) that the application of vin-
blastine alone requires a concentration of 250 µM (500 times
higher than that used in the combined therapy) to obtain the
same cytotoxic effect as that achieved with the combined
therapy. Such synergistic effect may be the result of the dual
effect of vinblastine, by enhancing HSV-tk gene expres-
sion, with a subsequent increase in the amount of the tox-
ic metabolite (GCV-TP), and arresting the cell cycle at the
mitosis level.
5. Conclusion
Overall, the results presented in this manuscript show that
the combination of vinblastine with the HSV-Tk/GCV gene
therapy, mediated by HSA-associated lipoplexes, results in a
significant synergistic effect. Such effect allows the use of a
much lower dose of the drug to achieve a therapeutic activity
and consequently to reduce side effects, thus highlighting the
potential of this combined strategy for future clinical anti-
tumoral applications.
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